The cardinal feature of systemic lupus erythematosus is the formation of anti-nuclear antibodies. In recent years, it has become clear that the nucleosome is a major autoantigen that drives this T cell-dependent autoimmune response, as exemplified by the presence of nucleosome-specific T helper cells and the high prevalence of nucleosome-specific autoantibodies. The only way to generate nucleosomes in vivo is by the process of apoptosis. There is growing evidence that in systemic lupus erythematosus apoptosis is disturbed, leading to the release of nucleosomes. Moreover, apoptosis-induced modifications of these autoantigens may render them more immunogenic, especially if the removal of apoptotic cells is insufficient. The first indications for the impaired clearance of apoptotic cells in systemic lupus erythematosus are emerging. Nucleosomes are also important for mediating tissue lesions, especially glomerulonephritis. In lupus nephritis nucleosomes, nucleosome-specific antibodies and nucleosome/IgG complexes have been identified in the glomerular immune deposits. Via their cationic histone part nucleosomes mediate the binding of anti-nuclear antibodies to intrinsic constituents of the glomerular basement membrane, such as the anionic heparan sulfate and collagen IV. Appreciation of this binding mechanism may lead to new treatment strategies, as shown for non-coagulant heparinoids.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/00041552-199905000-00005 | DOI Listing |
West J Nurs Res
January 2025
General Medical Department, Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China.
Background: Systemic lupus erythematosus (SLE) is characterized by a range of symptoms that often cluster together, impacting the quality of life (QoL) of affected individuals.
Objective: To delineate the composition of symptom clusters in patients with SLE and analyze their correlation with QoL, thus providing a basis for symptom management.
Methods: Using convenience sampling, 201 patients were recruited.
Mol Diagn Ther
January 2025
Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
Obecabtagene autoleucel (AUCATZYL) is a CD19-directed genetically modified autologous T cell immunotherapy which is being developed by Autolus for the treatment of hematological cancers and systemic lupus erythematosus. In comparison with other chimeric antigen receptor T (CAR T) therapies, obecabtagene autoleucel has a fast off-rate binder for CD19. Obecabtagene autoleucel received approval following positive results from the FELIX phase I/II trial in adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL), and it is the first CAR T therapy that does not have mandatory Risk Evaluation Mitigation Strategy monitoring requirements.
View Article and Find Full Text PDFCurr Opin Psychiatry
March 2025
Neuropsychiatry Unit, Instituto Nacional de Neurología y Neurocirugía, Ciudad de México.
Purpose Of Review: Autoimmune diseases such as systemic lupus erythematosus (SLE), multiple sclerosis (MS), and autoimmune encephalitis can directly and indirectly affect brain function, leading to cognitive dysfunction or well characterized neurocognitive syndromes. However, these are often poorly characterized in the literature. Here, we review evidence on clinical manifestations, risk factors, their assessment and outcomes, and evidence for underlying mechanisms and associated biomarkers, if available.
View Article and Find Full Text PDFCureus
December 2024
Pharmacy, Methodist University Hospital, Memphis, USA.
A 75-year-old woman with a history of systemic lupus erythematosus (SLE) presented with isolate ocular symptoms, including a left scleral hematoma, elevated erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP). Initial evaluation combined with isolated ocular symptoms raised concerns for giant cell arteritis rather than an SLE flare. Thus, prompt initiation of high-dose intravenous methylprednisolone (250 mg every six hours) was warranted.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!